Importantly, while skeletal muscle accounts for approximately 80% of insulin-stimulated glucose disposal [2], and is the primary site of insulin resistance in type 2 diabetes [3], none of the current pharmacotherapies specifically target skeletal muscle to enhance glucose disposal. Here, INS is linked to type 2 diabetes mellitus.